2022年志贺菌与产肠毒素大肠埃希菌疫苗会议(VASE):基于摘要的报告总结
全球非营利组织PATH于2022年11月29日至12月1日在美国华盛顿特区主办了第三届志贺菌与产肠毒素大肠埃希菌疫苗会议(VASE)。会议通过全体会议、海报、主题演讲和分组研讨会,展示了被忽视腹泻病原体(包括志贺菌、产肠毒素大肠埃希菌、弯曲杆菌和沙门菌)疫苗研发相关的重要进展。报告与讨论强调这些腹泻病原体对低中等收入国家婴幼儿健康的显著影响,反映对新肠道疫苗开发和许可的迫切需求。
要点
- 会议强调志贺菌、产肠毒素大肠埃希菌等腹泻病原体对低中等收入国家婴幼儿健康的显著影响。
- 会议反映对新肠道疫苗开发和许可的迫切需求。
- 会议探讨了疾病负担、疫苗价值评估、候选疫苗临床前与临床试验、新佐剂和免疫策略等主题。
核心结论
- 会议报告与讨论强调这些腹泻病原体对低中等收入国家婴幼儿健康的显著影响,反映对新肠道疫苗开发和许可的迫切需求。
研究设计与样本
- 全球非营利组织PATH于2022年11月29日至12月1日在美国华盛顿特区主办第三届VASE会议。
- 会议形式包括全体会议、海报、主题演讲和分组研讨会。
主要发现
- 会议报告与讨论强调这些腹泻病原体对低中等收入国家婴幼儿健康的显著影响。
- 口头与海报报告探讨了疾病全球负担与临床表现、流行病学及干预影响。
- 会议探讨了肠道病原体疫苗价值评估、候选疫苗临床前评价与肠道疾病模型。
- 会议探讨了临床试验与人类挑战模型中的候选疫苗、预测感染与疾病应答的宿主参数与基因组学。
- 会议探讨了新组学技术、新佐剂、疫苗递送平台、免疫策略及联合/同时接种疫苗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, on November 29 to December 1, 2022. With a combination of plenary sessions and posters, keynote presentations, and breakout workshops, the 2022 VASE Conference featured key updates on research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and Salmonella. The presentations and discussions highlighted the significant impact of these diarrheal pathogens, particularly on the health of infants and young children in low- and middle-income countries, reflecting the urgent need for the development and licensure of new enteric vaccines. Oral and poster presentations at the VASE Conference explored a range of topics, including: the global burden and clinical presentation of disease, epidemiology, and the impact of interventions; the assessment of the value of vaccines against enteric pathogens; preclinical evaluations of vaccine candidates and models of enteric diseases; vaccine candidates in clinical trials and human challenge models; host parameters and genomics that predict responses to infection and disease; the application of new omics technologies for characterization of emerging pathogens and host responses; novel adjuvants, vaccine delivery platforms, and immunization strategies; and strategies for combination/co-administered vaccines. The conference agenda also featured ten breakout workshop sessions on topics of importance to the enteric vaccine field, which are summarized separately. This article reviews key points and highlighted research presented in each of the plenary conference sessions and poster presentations at the 2022 VASE Conference.
引用
- Banerjee S, Barry EM, Baqar S, et al. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations. Vaccine. 2023. PMID: 38030421. doi:10.1016/j.vaccine.2023.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。